SCHEMBL23364147

SCHEMBL23364147

C[C@H]1CN(c2ccc(F)cc2)CCN1CC[C@H]1CC2(CCNCC2)C(=O)N1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 6/20 0.41
HTR1A P08908 3/20 0.36
HTR1D P28221 1/20 0.36
SLC6A4 P31645 1/20 0.36
ADAMTS5 Q9UNA0 1/20 0.34
CHRM4 P08173 1/20 0.34
ADORA2A P29274 2/20 0.33
POLB P06746 1/20 0.33
HTR2A P28223 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
GSK3B P49841 1/20 0.33
PARP1 P09874 3/20 0.33
TNK1 Q13470 3/20 0.33
TNK2 Q07912 1/20 0.33
HTR6 P50406 1/20 0.32
FAAH O00519 2/20 0.32
ADORA1 P30542 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23364101 1.00 HTR7 (0.41) HTR7HTR1AHTR1DSLC6A4ADAMTS5
SCHEMBL23364100 1.00 HTR7 (0.41) HTR7HTR1AHTR1DSLC6A4ADAMTS5
SCHEMBL23363967 0.87 HTR7 (0.43) HTR7HTR1AHTR1DSLC6A4ADAMTS5
SCHEMBL24850756 0.87 HTR7 (0.43) HTR7HTR1AHTR1DSLC6A4ADAMTS5
SCHEMBL23364133 0.87 CHRM4 (0.39) HTR7HTR1AHTR1DSLC6A4ADAMTS5
SCHEMBL23363972 0.87 HTR7 (0.43) HTR7HTR1AHTR1DSLC6A4ADAMTS5
SCHEMBL23364132 0.87 CHRM4 (0.39) HTR7HTR1AHTR1DSLC6A4ADAMTS5
SCHEMBL23364136 0.87 CHRM4 (0.39) HTR7HTR1AHTR1DSLC6A4ADAMTS5
SCHEMBL21565367 0.86 HTR7 (0.53) HTR7HTR1AADAMTS5HTR2AHTR6
SCHEMBL21552610 0.86 HTR7 (0.53) HTR7HTR1AADAMTS5HTR2AHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002383-A1 NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE PRAEVENTIX, LLC 2023-01-05 US disclosed
US-20230002383-A1 NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE PRAEVENTIX, LLC 2023-01-05 US disclosed
EP-4058455-A1 NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE Temple University - Of The Commonwealth System of Higher Education (US) 2022-09-21 EP disclosed
CN-115003675-A Novel functionalized lactams as 5-hydroxytryptamine receptor 7 modulators and methods of use thereof 英联邦高等教育系统坦普尔大学 2022-09-02 CN disclosed
WO-2021097116-A1 NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002383-A1 NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE HTR7, HTR1A, HTR2C HTR7 1/4885HTR1A 2/4885HTR1D 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.